July 2023 in “SKIN The Journal of Cutaneous Medicine” Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
48 citations
,
July 2023 in “Pediatric Dermatology” Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
2 citations
,
June 2024 in “Dermatology” Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine” July 2025 in “Journal of the European Academy of Dermatology and Venereology” March 2025 in “Journal of Investigative Dermatology” March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
Hepatitis B vaccination can trigger HSP, and vitamin D correction and tonsillectomy can effectively manage it.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
1 citations
,
December 2023 in “Value in Health” The EQ-5D does not fully capture the impact of alopecia areata on quality of life.
September 2025 in “Cancer Innovation” Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
January 2023 in “Figshare” Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
January 2023 in “Journal of The American Society of Nephrology” Metatrials could improve clinical research in nephrology by speeding up data collection and overcoming challenges like patient recruitment.
38 citations
,
January 2001 in “Neuroepidemiology” The current system can't fully test all combination treatments, so alternative methods and regulatory flexibility are needed.
More hair-loss studies are needed with standardized outcomes and diverse participants.
April 2019 in “Biometrics” The new clinical trial design is promising but needs real-world trials to test its effectiveness and possible enhancements.
2 citations
,
November 2015 in “Journal of Investigative Dermatology Symposium Proceedings” A standard protocol for alopecia areata clinical trials was created to improve consistency and encourage more research.
June 2026 in “Value in Health” January 2023 in “Figshare” Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.
November 2010 in “Value in Health” Using a call center to collect data in a trial for eye disease in diabetics led to high response rates and very little missing information.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
7 citations
,
August 2023 in “Therapeutic Innovation & Regulatory Science” A new method uses expert reviews of home videos to objectively assess children's developmental milestones in single-arm trials.